Better Health for All

Mereo BioPharma Group plc's core business is entirely focused on developing therapeutics for rare diseases with high unmet medical needs, such as Osteogenesis Imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD).

Clinical trial data for setrusumab and alvelestat show potential for improved bone density and reduced fractures in OI, and for slowing lung function decline in AATD-LD. The company has no revenue from product sales, with revenue primarily from licensing and collaboration agreements. All of the company's R&D expenses, which were £14.4 million in 2024, are dedicated to developing these health-improving therapeutics. The company discloses clinical trial data and safety information, and has received Orphan Drug, PRIME, Breakthrough Therapy, and Fast Track designations for its lead candidates, indicating regulatory recognition of their potential and ethical conduct.

Fair Pay & Worker Respect

No specific data points were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. The annual reports explicitly state 'No data on' or 'Not mentioned' for living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

While CEO compensation is mentioned, median employee compensation is not, preventing the calculation of the pay ratio.

Honest & Fair Business

Mereo BioPharma Group plc reported no material legal proceedings as of December 31, 2024, and no regulatory fines or compliance issues were mentioned in the past three years.

The company's 2024 financial statements were restated due to a voluntary change in accounting policy. A full scope audit was performed on the Group by PricewaterhouseCoopers LLP, covering 100% of the loss before tax. The company has a formal whistleblower policy, including a confidential and anonymous hotline, web form, and direct reporting to the Audit Committee for concerns regarding accounting, internal controls, fraud, or auditing matters, emphasizing confidentiality and anonymity. A Code of Business Conduct and Ethics and an Anti-Bribery and Anti-Corruption Policy are in place, outlining prohibited behavior and due diligence for third parties, but specific enforcement details or effectiveness metrics are not provided. The independent audit by PricewaterhouseCoopers LLP serves as third-party verification of financial statements.

Kind to Animals

Mereo BioPharma Group plc is listed on the Cruelty Free Investing list for exploiting animals because the company conducts animal testing for medical analysis and clinical research.

The company's animal testing policy is vague, as it allows for routine non-essential testing to continue. Annually, Mereo BioPharma uses between 50,000 and 100,000 animals in its testing, with no transparent reduction targets reported.

No War, No Weapons

Mereo BioPharma Group plc is a biopharmaceutical company focused on rare diseases, with its core business centered on research, development, and commercialization of therapeutics.

The company's activities do not involve arms manufacturing, military contracts, or conflict facilitation. There is no evidence of revenue from arms or defense contracts, nor any investment in dual-use technologies. The company does not engage in sales to embargoed regimes, defense-related lobbying, or military AI applications. Its operations are not in conflict-affected areas, and its corporate documents, including articles of association, do not mention any involvement in weapons or defense-related activities.

Planet-Friendly Business

Mereo BioPharma Group plc reported total Scope 1, 2, and 3 greenhouse-gas emissions of 15 tCO₂e for 2024, which increased from 13 tCO₂e in 2023.

Emissions were 13 tCO₂e in 2022 and 15 tCO₂e in 2021. The company has a commitment to sourcing electricity from renewable sources, but no specific percentage of renewable energy consumption is provided. Energy-saving measures were implemented during an office refurbishment in 2021, including insulation, motion-activated lighting, and heating system changes. However, there is no evidence that any of the company's facilities hold green building certifications.

Safe & Smart Tech

The provided articles do not contain specific, quantifiable data points for any of the Safe & Smart Tech KPIs. While the company's annual report mentions a cybersecurity risk management program based on UK Cyber Essentials and NIST CSF, along with employee training and vulnerability assessments, it lacks the necessary metrics such as investment percentages, breach severity details, training effectiveness rates, or specific compliance outcomes to be scored against the rubric's quantitative thresholds.

No information on AI ethics, privacy certifications, encryption implementation, or user data controls is provided.

Zero Waste & Sustainable Products

The provided articles, including Mereo BioPharma Group plc's annual reports for 2022 and 2024, and its Code of Business Conduct and Ethics, explicitly state that no specific zero waste or sustainable product metrics are detailed.

The company's focus is on drug development, not product manufacturing or waste management. Consequently, no concrete data points or metrics related to waste management, product sustainability, or circular economy principles are available to score any of the KPIs under the 'Zero Waste & Sustainable Products' value.